

NCT ID	NCT04724239
Title	A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
Phase	Phase 2
Date Added	2021-01-26
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	chidamide, IBI305, Sintilimab
Tags	MSS/ MMRp

NCT ID	NCT03093116
Title	A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Phase	Phase 1, Phase 2
Date Added	2017-03-28
Location	California, United States Colorado, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Australia Belgium Canada China Denmark France Germany Hong Kong Hungary Italy Japan Korea, Republic of Netherlands Poland Singapore Spain Taiwan United Kingdom
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting

Drugs	Oral repotrectinib (TPX-0005)
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05677113
Title	A Study of QBECO Versus Placebo in the Treatment of Colorectal Cancer That Has Spread to the Liver
Phase	Phase 2
Date Added	2023-01-10
Location	Canada
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Placebo, QBECO
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05107674
Title	A Study of NX-1607 in Adults With Advanced Malignancies
Phase	Phase 1
Date Added	2021-11-04
Location	California, United States Colorado, United States Illinois, United States North Carolina, United States Oklahoma, United States Texas, United States Virginia, United States Washington, United States United Kingdom
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	NX-1607
Tags	MSS/ MMRp
NCT ID	NCT06218914
Title	A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation
Phase	Phase 1
Date Added	2024-01-23
Location	California, United States Kansas, United States Missouri, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06792695
Title	A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Phase Phase 2
Date Added 2025-03-25
Location Arizona, United States
California, United States
District of Columbia, United States
Illinois, United States
Maryland, United States
Massachusetts, United States
Minnesota, United States
New York, United States
Ohio, United States
Texas, United States
Australia
Canada
China
France
Germany
Italy
Korea, Republic of
Spain
Taiwan
United Kingdom
Prior IO Allowed No
CRC-directed Yes
Status Recruiting
Drugs
Tags MSS/ MMRp

NCT ID NCT04008030
Title A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)
Phase Phase 3
Date Added 2019-07-05

Location	California, United States Colorado, United States Illinois, United States New York, United States Oregon, United States Pennsylvania, United States Texas, United States Virginia, United States Argentina Australia Austria Belgium Brazil Canada Chile China Czechia Denmark France Germany Greece Ireland Italy Japan Netherlands Norway Puerto Rico Romania Spain Turkey United Kingdom
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Bevacizumab, cetuximab, fluorouracil, Irinotecan, Leucovorin, oxaliplatin
Tags	MSI-H/ MMRd
<hr/>	
NCT ID	NCT05328908
Title	A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
Phase	Phase 3
Date Added	2022-04-14

Location	Arkansas, United States California, United States Connecticut, United States Florida, United States Georgia, United States Idaho, United States Indiana, United States Massachusetts, United States Michigan, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Virginia, United States Wisconsin, United States Argentina Australia Austria Belgium Canada Chile China Czechia France Germany Italy Japan Korea, Republic of Netherlands Poland Puerto Rico Singapore Spain Sweden Switzerland Taiwan
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Nivolumab-relatlimab FDC, Regorafenib, TAS-102, Lonsurf, Opdivo, Stivarga
Tags	MSS/ MMRp
NCT ID	NCT04426669
Title	A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
Phase	Phase 1, Phase 2
Date Added	2020-06-11
Location	Minnesota, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Aldesleukin, Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes (TIL)
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT01351103
Title	A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Phase	Phase 1

Date Added	2011-05-10
Location	California, United States Maryland, United States Massachusetts, United States Michigan, United States Texas, United States Canada France Germany Italy Netherlands Spain
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	LGK974, PDR001
Tags	MSS/ MMRp